Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02263820 · ClinicalTrials.gov registry record
Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography
A clinical trial, sponsored by Sapere Bio.
- Completed
- Registry status
- 185
- Enrollment target
NCT02263820 is a clinical trial that has completed, run by Sapere Bio. The registered enrollment target is 185 participants.
The verdict
NCT02263820 has completed, sponsored by Sapere Bio.
- COMPLETED
- Registry status
- 185 participants
- Enrollment target
Study Summary
Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI. The development of CI-AKI after cardiac catheterization is associated with a significant increase in both short-term and long-term mortality and morbidities, as well as an increase in length of stay and cost. The only marker of renal function that has predictive ability is creatinine and it has significant limitations in identifying patients who will develop AKI. Therefore, a diagnostic test for predicting CI-AKI risk would have widespread clinical utility. The primary purpose of this study is to measure the association between baseline expression of senescence markers in blood using SenesceTest and the occurrence of CI-AKI post cardiac catheterization.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02263820
The ClinicalTrials.gov registry entry for NCT02263820 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sapere Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02263820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02263820 about?
NCT02263820 is a clinical study titled "Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography". Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI. The development of CI-AKI after cardiac catheterization is associated with a significant increase in both sho...
What is the current status of trial NCT02263820?
This trial is currently completed. The enrollment target is 185 participants. The study started on 2015-01. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT02263820?
This trial is sponsored by Sapere Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.